The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer

Despite significant advances made in cancer treatment, the development of therapeutic resistance to anticancer drugs represents a major clinical problem that limits treatment efficacy for cancer patients. Herein, we focus on the response and resistance to current antiangiogenic drugs and immunothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Leong, Alessandra, Kim, Minah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698611/
https://www.ncbi.nlm.nih.gov/pubmed/33217955
http://dx.doi.org/10.3390/ijms21228689

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698611/
https://www.ncbi.nlm.nih.gov/pubmed/33217955
http://dx.doi.org/10.3390/ijms21228689

Ejemplares similares